|
Originally published In Press as doi:10.1074/jbc.M202493200 on June 28, 2002
J. Biol. Chem., Vol. 277, Issue 36, 32830-32836, September 6, 2002
Hyposialylation of Integrins Stimulates the Activity of Myeloid
Fibronectin Receptors*
Alexis C.
Semel ,
Eric C.
Seales ,
Anuj
Singhal ,
Elizabeth
A.
Eklund§,
Karen J.
Colley¶, and
Susan L.
Bellis
From the Department of Physiology and Biophysics,
University of Alabama at Birmingham, Birmingham, Alabama, 35294, the § Lakeside Veterans Administration Hospital,
Northwestern University Medical School and the Robert H. Lurie
Comprehensive Cancer Center, Chicago, Illinois, 60611, and the
¶ Department of Biochemistry and Molecular Biology, University of
Illinois College of Medicine, Chicago, Illinois, 60612
Received for publication, March 14, 2002, and in revised form, June 24, 2002
 |
ABSTRACT |
Despite numerous reports suggesting that
1 integrin receptors undergo differential
glycosylation, the potential role of N-linked carbohydrates
in modulating integrin function has been largely ignored. In the
present study, we find that 1 integrins are
differentially glycosylated during phorbol ester (PMA)-stimulated
differentiation of myeloid cells along the monocyte/macrophage lineage.
PMA treatment of two myeloid cell lines, U937 and THP-1, induces a
down-regulation in expression of the ST6Gal I sialyltransferase.
Correspondingly, the 1 integrin subunit becomes
hyposialylated, suggesting that the 1 integrin is a
substrate for this enzyme. The expression of hyposialylated
1 integrin isoforms is temporally correlated with
enhanced binding of myeloid cells to fibronectin, and, importantly, fibronectin binding is inhibited when the Golgi disrupter, brefeldin A,
is used to block the expression of the hyposialylated form. Consistent
with the observation that cells with hyposialylated integrins are more
adhesive to fibronectin, we demonstrate that the enzymatic removal of
sialic acid residues from purified 5 1 integrins stimulates fibronectin binding by these integrins. These data
support the hypothesis that unsialylated 1 integrins are more adhesive to fibronectin, although desialylation of
5 subunits could also contribute to increased
fibronectin binding. Collectively our results suggest a novel mechanism
for regulation of the 1 integrin family of cell adhesion receptors.
 |
INTRODUCTION |
The U937 and THP-1 myeloid cell lines have been widely used to
study myeloid differentiation along the monocyte/macrophage lineage.
Following treatment with the phorbol ester, phorbol myristate acetate
(PMA),1 U937 and THP-1 cells
express proteins characteristic of terminally differentiated cells,
including components of the respiratory burst oxidase
(gp91phox, p67phox, and p47phox), granule
proteins (myeloperoxidase and elastase) and cell adhesion receptors
(CD11, CD18, and CD49e) (1, 2). Consistent with the expression of these
proteins, PMA-treated cells acquire functions characteristic of mature
phagocytes, including respiratory burst activity, phagocytosis, and
increased adhesiveness to endothelial cells as well as to extracellular
matrix components such as fibronectin. In vivo, the
increased adhesiveness of monocyte/macrophage cells contributes to the
extravasation of cells from the vasculature and may further tether
cells at sites of inflammation within the tissues.
The PMA-induced adhesion of myeloid cells to extracellular matrix
components is mediated by the integrin family of cell adhesion receptors. Integrins are heterodimeric glycoproteins composed of one
and one subunit (3, 4). The specificity of integrin heterodimers is dictated by the pairing of various and subunits; for example, the 5 1 integrin
(VLA5) associates with fibronectin, whereas the
2 1 integrin (VLA2) binds to either
collagen or laminin. The binding of integrins to ligand, followed by
receptor clustering, initiates signal transduction events that
ultimately regulate many fundamental cellular processes, including
initiation of gene transcription, cell survival, cell
motility/invasiveness, and cytoskeletal reorganization.
The mechanisms that underlie the PMA-induced adhesion of differentiated
myeloid cells to fibronectin have not been well-defined. Several groups
have reported that sustained PMA treatment of U937 cells stimulates
both the transcription and cell surface expression of the
5 and 1 integrin subunits (2, 5-7).
However, untreated U937 cells express an abundant amount of the
5 1 integrin heterodimer, and yet these
cells do not bind to fibronectin. This finding suggests that these
receptors are in an inactive state. Increased expression may therefore
contribute to enhanced binding but is unlikely to fully account for the
robust cell adhesion that occurs following PMA treatment. Intriguingly,
it has been shown that PMA treatment of U937 and THP-1 cells induces
the synthesis of a 1 integrin subunit with altered
N-glycosylation (8). Hence, PMA not only increases the
expression of 1 integrins but also directs the synthesis
of 1 integrins that are structurally different from the
1 integrins expressed by untreated cells.
In the present study we provide evidence implicating differentially
glycosylated 1 integrins as mediators of the
PMA-dependent fibronectin binding of U937 and THP-1 cells.
Our studies show that PMA treatment causes a down-regulation in the
ST6Gal I sialyltransferase, a trans-Golgi enzyme that adds
the negatively charged sugar, 2-6-linked sialic acid, to
glycoproteins. In turn, 1 integrins that are synthesized
following PMA treatment are hyposialylated and demonstrate enhanced
fibronectin-binding capability. Collectively, our results suggest a
novel mechanism for the regulation of 1 integrin
function during myeloid differentiation.
 |
EXPERIMENTAL PROCEDURES |
Cell Culture
A U937 cell subclone selected for sensitivity to granulocyte
macrophage-colony stimulating factor was obtained from Dr. Andrew Kraft
(University of Colorado, Denver, CO). THP-1 cells were obtained from
the American Type Culture Collection (ATCC). U937 cells were maintained
in Dulbecco's modified Eagle's medium containing 10% fetal bovine
serum and gentamicin, whereas THP-1 cells were maintained in RPMI 1640 media with 10% fetal bovine serum and gentamicin. The PMA-resistant
cell line, PRU, was derived from U937 cell cultures by treating U937
cells with 100 ng/ml PMA for 36 h and then by selecting cells that
did not adhere to the tissue culture dish. The PMA-containing media was
replaced with normal media, and cells were grown for 72 h. This
population of cells was then challenged again with 100 ng/ml PMA for
36 h, and nonadherent cells were again collected. The nonadherent
cells were diluted and seeded into 96-well dishes to obtain single-cell
clones. Clones were subsequently expanded and evaluated for resistance
to PMA-induced cell adhesion.
Western Blotting
U937 cells were treated with or without 50 ng/ml PMA for 15 h. Cells were then lysed in 50 mM Tris-HCl buffer (pH 7.4)
containing 1% Triton X-100, 0.5 mM phenylmethylsulfonyl
fluoride, 20 µg/ml leupeptin, 4 mM sodium fluoride, and
200 µM sodium pervanadate ("lysis buffer"). Protein
concentrations were determined using a modified Bradford assay (Sigma
Chemical Co.). One to two hundred micrograms of cell lysate were
resolved by reducing SDS-PAGE, and proteins were subsequently
transferred to polyvinylidene difluoride membrane. Membranes were
blocked for 1-2 h with 3% nonfat dry milk. After blocking, blots were
incubated for 2-4 h with a monoclonal antibody specific for the
1 integrin (Transduction Labs) or with a polyclonal
antibody specific for ST6Gal I (provided by Dr. Karen Colley). Blots
were then washed several times with Tris-buffered saline containing
0.05% Tween-20 (TBST). Following the washes, blots were incubated for
1 h with a horseradish-peroxidase (HRP)-coupled secondary antibody
(Amersham Biosciences), then washed again with TBST. Blots were
incubated with a luminescent HRP substrate (Amersham Biosciences) for 1 min, and positive signals were detected using the enhanced
chemiluminescence method.
PNGase F Treatment--
Cell lysates were boiled in buffer
containing 1% SDS to denature cellular proteins. Cell lysates were
then diluted 5-fold in PBS, and Triton X-100 was added to a final
concentration of 1%. The deglycosylating enzyme, PNGase F (Roche
Molecular Biochemicals), was added to a final concentration of 10 units/ml, and lysates were incubated overnight at 37 °C.
Sialidase Treatment--
Cell lysates were treated for 3 h
at 37 °C in the presence or absence of 10 milliunits/ml
protease-free Clostridium perfringens sialidase (Roche
Molecular Biochemicals). Desialylated or control lysates were then
boiled in SDS-PAGE sample buffer and subsequently subjected to Western
blot analysis.
Lectin Affinity Analyses
Six hundred micrograms of cell lysate protein was incubated for
3 h at 4 °C with 4 µg of either biotinylated SNA or
biotinylated MAA (Vector Laboratories). 20 µl of streptavidin-agarose
(Sigma Chemical Co.) was then added, and samples were incubated for an additional 2 h at 4 °C with rotation. Lectin/glycoprotein
complexes were collected by brief centrifugation and washed three times with lysis buffer, followed by one wash with PBS. Glycoproteins were
released from the complexes by boiling in SDS-PAGE sample buffer. The
glycoproteins were resolved by SDS-PAGE, then immunoblotted to detect
the 1 integrin.
Cell Attachment Assays
Cells were treated with or without 50 ng/ml PMA then were seeded
onto tissue culture dishes that had been precoated overnight at 4 °C
with 20 µg/ml fibronectin. Cells were allowed to adhere for 15 h
at 37 °C. Following this incubation, nonadherent cells were removed
from the dishes by washing the dishes with PBS. Adherent cells were
fixed for 40 min in 3.7% formaldehyde then stained for 40 min with
0.1% crystal violet. Stained cells were subsequently solubilized in
10% acetic acid, and absorbance spectrophotometry (540 nm) was used to
quantify the amount of dye in each sample.
Integrin Function Blocking Studies--
Cells were incubated for
1 h at 37 °C with a function blocking antibody specific for
either the 1 integrin subunit (Invitrogen) or the
2 or 3 integrin subunits (Chemicon
International). A nonspecific, isotype-matched mouse IgG (Chemicon
International) was included as a control. Following incubation with the
function-blocking antibody (final concentration = 10 µg/ml), 50 ng/ml PMA was added to the samples, and cells were seeded onto
fibronectin-coated dishes. Cell adhesion was quantified as described above.
Cell Adhesion Time Course--
Cells were resuspended in media
containing 50 ng/ml PMA and were then placed in low attachment tissue
culture dishes (BD Transduction Laboratories) to eliminate cell
adhesion to the dishes. At the designated time points, aliquots of
cells were removed from the nonattaching dishes and seeded onto
standard tissue culture dishes that had been precoated with 20 µg/ml
fibronectin. Cells were allowed to adhere for 40 min, and then adhesion
was quantified as described above.
Brefeldin A--
At selected time points during the adhesion
time course experiment, brefeldin A (Sigma) was added to the media at a
final concentration of 20 µg/ml.
Sialidase Treatment of Purified Integrins and Modified ELISA
Integrin Binding Assay
Purified 5 1 integrins (Chemicon
International) were resuspended to a final concentration of 4.4 µg/ml
in 50 mM Tris buffer containing 150 mM NaCl, 2 mM MgCl2, 0.1 mM CaCl2,
and 0.1% Triton X-100 ("ELISA buffer"), adjusted to pH 6.5. Two
hundred milliunits of agarose-conjugated Vibrio cholerae
neuraminidase (Calbiochem) was added to the integrin solution, and
samples were incubated for 3 h at 37 °C with rotation. As a
control, an equivalent amount of 5 1
integrin was incubated in pH 6.5 ELISA buffer for 3 h at 37 °C
in the absence of neuraminidase. Following the 3-h incubation, the
buffer was adjusted to pH 7.4 by dilution with pH 8.0 ELISA buffer.
Samples were centrifuged to precipitate the agarose-conjugated neuraminidase, and the integrin-containing supernatants were loaded onto 12-well tissue culture dishes that had been precoated with varying
amounts of fibronectin. A final amount of 350 ng of
neuraminidase-treated 5 1 integrin (or
control integrin) was added to each fibronectin-coated well. Treated or
untreated samples were also loaded onto wells that had been precoated
with denatured BSA, rather than fibronectin, to control for nonspecific
binding. Purified integrins were allowed to adhere to BSA or
fibronectin for 1 h at 37 °C. The wells were then washed three
times with ELISA buffer. The anti- 1 integrin monoclonal
antibody, MAB2000, was subsequently added to the wells (1:1000
dilution, Chemicon International), and the samples were incubated for
an additional hour at 37 °C. The MAB2000 antibody recognizes both
native and denatured 1 integrins and will precipitate 5 1 from both control and PMA-treated U937
and THP-1 cells (data not shown); therefore, this antibody is
insensitive to changes in glycosylation. Following the incubation with
MAB2000, wells were washed three times with ELISA buffer. An
HRP-conjugated anti-mouse IgG was added, and samples were incubated for
1 h at 37 °C. Samples were washed three times and then
incubated for 30 min at 37 °C with the colorimetric HRP substrate,
Chromogen (BIOSOURCE International). The amount of
integrin bound to matrix-coated wells was quantitated by absorbance
spectroscopy using a wavelength of 450 nm. Values for specific binding
were obtained by subtracting the BSA-dependent binding
("nonspecific") from the total fibronectin binding.
 |
RESULTS |
1 Integrins from PMA-treated U937 and THP-1 Cells
but Not PMA-resistant U937 cells (PRU cells) Exhibit Altered
N-Glycosylation, as Evidenced by Increased Electrophoretic
Mobility--
U937 or THP-1 myeloid cells were incubated for 15 h
in the presence of 50 ng/ml PMA, a treatment that is known to induce
the differentiation of myeloid cells along the monocyte/macrophage lineage. Following this incubation, PMA-treated and untreated cells
(control) were lysed, and lysates were subsequently resolved by
SDS-PAGE. 1 integrins were detected by Western blot
analysis. As shown in Fig. 1A,
the mature 1 integrins harvested from PMA-treated U937
and THP-1 cells migrated more rapidly during SDS-PAGE than 1 integrins from untreated U937 and THP-1 cells. The
electrophoretic mobility of the precursor 1 integrin
isoform was unaffected by PMA treatment. To determine whether the
change in the mobility of mature 1 integrins was due to
altered N-glycosylation, lysates were treated with PNGase F,
an enzyme that removes N-linked carbohydrates from
glycoproteins. Subsequent Western blot analysis of PNGase F-treated
lysates revealed that deglycosylated 1 integrins from control and PMA-treated cells had identical mobility (Fig.
1B), indicating that the differential mobility of
glycosylated integrins was due to an alteration in the composition of
N-linked carbohydrates. Most probably, altered glycosylation
occurred at the level of the Golgi, in that the partially glycosylated
precursor 1 integrin, an endoplasmic reticulum-localized
isoform (9, 10), did not exhibit differential electrophoretic mobility
in response to PMA.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 1.
The 1
integrins harvested from PMA-treated U937 and THP-1 cells, but not PRU
cells, demonstrate more rapid electrophoretic mobility due to altered
N-glycosylation. A, U937, THP-1, or
PRU cells were incubated in the presence or absence of 50 ng/ml PMA for
15 h. Cells were then lysed in 50 mM Tris buffer
containing 1% Triton X-100 and protease inhibitors. Lysates were
resolved by SDS-PAGE then Western-blotted to detect the
1 integrin. The mature 1 integrins of
PMA-treated U937 and THP-1 cells exhibited more rapid electrophoretic
mobility as compared with untreated U937 and THP-1 cells (control). The
precursor 1 integrin species observed in U937 and PRU
cells is a partially glycosylated, endoplasmic reticulum-resident
integrin isoform (9, 10). B, cell lysates were treated with
the deglycosylating enzyme, PNGase F (see "Experimental
Procedures") and were then subjected to Western blot analysis to
detect the 1 integrin. No differences were observed in
the electrophoretic mobility of 1 integrins from PNGase
F-treated lysates, suggesting that the previously observed differences
in mobility (A) were due to alterations in
N-glycosylation.
|
|
One of the hallmarks of myeloid differentiation is increased cell
adhesiveness to a variety of extracellular matrix components. To
determine whether the expression of an altered 1
integrin glycoform was associated with myeloid differentiation, we
evaluated the effects of PMA on the electrophoretic mobility of
1 integrins harvested from the PRU cell line, a U937
subclone that does not exhibit increased cell adhesiveness in response
to PMA (see "Experimental Procedures"). In contrast to
PMA-sensitive U937 and THP-1 cells, PMA did not cause altered
electrophoretic mobility of mature 1 integrins from PRU
cells (Fig. 1A).
PMA Induces a Loss in 2-6 Sialic Acid Residues from the
1 Integrin--
Previous studies of 1
integrin glycosylation in other cell types have suggested that
1 integrins can undergo changes in the content of sialic
acids (11-14). To examine whether PMA caused a difference in
1 integrin sialylation, we used a lectin affinity approach. Briefly, cell lysates containing an equal amount of 1 integrin (see Fig. 1A) were incubated with
a biotinylated lectin, followed by the addition of streptavidin coupled
to agarose beads. Lectin/glycoprotein complexes were precipitated by
centrifugation, washed, and resolved by SDS-PAGE. The 1
integrin was then detected by Western blot analysis. Two lectins were
examined; SNA, a lectin that recognizes 2-6-linked sialic acids,
and MAA, a lectin that binds to 2-3-linked sialic acids. As shown
in Fig. 2A, 1
integrins from untreated U937 and THP-1 cells were precipitated by SNA, suggesting that the 1 integrins of undifferentiated
myeloid cells typically carry 2-6-linked sialic acid residues.
However, SNA failed to precipitate 1 integrins from the
lysates of PMA-treated U937 and THP-1 cells. These data suggest that
PMA treatment of U937 and THP-1 cells stimulated the expression of
1 integrins that lack in 2-6 sialic acids. Unlike
U937 and THP-1 cells, PMA-resistant PRU cells did not express
hyposialylated 1 integrins following PMA treatment (Fig.
2A), consistent with previous data suggesting that the
1 integrins of PRU cells do not undergo altered
glycosylation in response to PMA (Fig. 1A). In contrast to
the differential recognition of 1 integrins by the SNA
lectin, the 2-3-specific lectin MAA failed to precipitate
1 integrins from any of the cell lysates tested.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 2.
The 1
integrins of PMA-treated U937 and THP-1 cells do not carry
2-6-linked sialic acid residues, as evidenced by
the lack of recognition of these integrins by SNA lectin.
A, cell lysates from U937, THP-1, and PRU cells were
incubated for 4 h with 4 µg of biotinylated SNA, a lectin that
specifically recognizes 2-6-linked sialic acid residues.
Streptavidin-coupled agarose was subsequently added, and lysates were
incubated for another 2 h at 4 °C. The SNA-glycoprotein
complexes were collected by brief centrifugation and then washed
extensively with lysis buffer. The complexes were boiled in SDS-PAGE
sample buffer, resolved by SDS-PAGE, then Western-blotted to detect the
1 integrin. The 1 integrins of
PMA-treated U937 and THP-1 cells were not precipitated by SNA,
suggesting that PMA treatment induces the expression of
1 integrins that are lacking in 2-6 sialic acids.
B, lysates from untreated U937 cells (control lysates) were
incubated with C. perfringens sialidase to cleave sialic
acids from lysate glycoproteins. These lysates, along with samples of
control and PMA-treated U937 cell lysates, were resolved by SDS-PAGE
and Western-blotted to detect the 1 integrin. The
electrophoretic mobility of mature 1 integrins from
sialidase-treated lysates was essentially identical to that of
hyposialylated 1 integrins expressed by PMA-treated
cells.
|
|
The SNA lectin analyses suggested that the more rapid electrophoretic
mobility of 1 integrins from PMA-treated U937 and THP-1 cells (Fig. 1A) resulted from a PMA-induced loss in 2-6
sialic acids. To further confirm that altered sialylation represented the major PMA-induced change in glycosylation, we compared the electrophoretic mobility of 1 integrins harvested from
PMA-treated cells with that of 1 integrins from control
cell lysates that had been desialylated by the enzyme, C. perfringens sialidase (Roche Molecular Biochemicals). Briefly,
cell lysates were incubated for 3 h at 37 °C in the presence or
absence of sialidase. Following this incubation, the lysates were
resolved by SDS-PAGE then Western blot analysis was done for the
1 integrin. As shown in Fig. 2B, the
electrophoretic mobility of control cell 1 integrins
that had been enzymatically desialylated was essentially identical to
that of the hyposialylated 1 integrins expressed by
PMA-treated cells.
PMA Treatment Causes a Down-regulation in ST6Gal I, the Golgi
Enzyme That Adds 2-6-linked Sialic Acids--
Given that PMA
treatment of U937 and THP-1 cells induced the expression of
1 integrins that were lacking in 2-6 sialic acids, we hypothesized that PMA caused a down-regulation in the enzyme that
directs 2-6 sialylation, the ST6Gal 1 sialyltransferase. Accordingly, we used Western blot analysis to examine the protein levels of ST6Gal 1 in treated and untreated cell lysates. As shown in
Fig. 3, PMA caused a down-regulation of
ST6Gal 1 in U937 and THP-1 cell lines but not in the PMA-resistant PRU
cell line. Duplicate samples were also blotted for -actin as a
loading control.

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 3.
PMA induces a down-regulation in the enzyme
that adds 2-6-linked sialic acid residues,
the ST6Gal I sialyltransferase. Lysates from control and
PMA-treated U937, THP-1, and PRU cells were Western-blotted to detect
the ST6Gal I sialyltransferase. In addition, duplicate samples were
blotted for -actin as a loading/lysis control. As shown, PMA caused
a down-regulation in ST6Gal I in U937 and THP-1 cells but not in PRU
cells.
|
|
Expression of a Hyposialylated 1 Integrin Glycoform
Is Associated with Enhanced Cell Binding to Fibronectin--
To
determine whether the expression of a hyposialylated 1
integrin glycoform was correlated with an alteration in integrin function, we examined cell adhesion to fibronectin. U937, THP-1, and
PRU cells were incubated in the presence or absence of PMA for 15 h and were then examined for adhesiveness to fibronectin using a
standard colorimetric assay (see "Experimental Procedures"). As
shown, U937 and THP-1 demonstrated enhanced binding to fibronectin following PMA treatment, whereas the binding of PRU cells was unaffected by PMA (Fig. 4A).
The PMA-dependent binding of U937 cells to fibronectin
resulted from some change in the activity of 1
integrins, because binding was inhibited by antibodies that block the
function of 1 but not 2 or
3 integrins (Fig. 4B).

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 4.
PMA-treated U937 and THP-1 cells, but not PRU
cells, demonstrate enhanced binding to fibronectin. A,
U937, THP-1, and PRU cells were incubated for 15 h in the presence
or absence of 50 ng/ml PMA and then evaluated for cell adhesion to
fibronectin using a standard colorimetric assay. Briefly, cells were
fixed in 3.7% formaldehyde then stained with crystal violet. Stained
cells were subsequently solubilizing in 10% acetic acid, and adhesion
was quantified by measuring the absorbance of the samples at 540 nm.
Data shown represent the mean ± S.E. for three experiments
performed in duplicate. B, antibodies that block the
function of either 1, 2, or
3 integrins were added to cell suspensions and incubated
for 1 h at 37 °C. A nonspecific, isotype-matched IgG was also
included as a control. Following the incubation with blocking antibody,
PMA was added to the antibody-containing solutions, and cells were
incubated for an additional 15 h. Cell adhesion to fibronectin was
then evaluated as described above. Data shown represent the mean and
S.E. of three experiments performed in duplicate.
|
|
Expression of a Hyposialylated 1 Integrin Is
Temporally Correlated with Enhanced Cell Adhesion to
Fibronectin--
We next examined whether the expression of a
hyposialylated 1 integrin isoform was temporally
correlated with PMA-induced cell binding to fibronectin. To this end,
we established a time course for PMA-stimulated cell adhesion to
fibronectin. Briefly, cells were treated with PMA and then held in low
attachment tissue culture dishes for varying time points. Cells were
subsequently seeded onto fibronectin-coated standard tissue culture
dishes, and adhesion was quantitated as described previously. As shown, PMA rapidly stimulated the binding of cells to fibronectin (Fig. 5A). However, after this
initial increase, cell adhesiveness appeared to diminish between 3 and
5 h and then rise again from 7 to 15 h. We anticipated that
the expression of a hyposialylated integrin would be associated with
the later, more prolonged phase of cell adhesion, rather than the
early, rapid phase, given that trafficking of integrins through the
endoplasmic reticulum and Golgi typically requires several hours in
most cell types (15-18). To determine whether the expression of a
hyposialylated integrin was temporally correlated with the delayed
phase of cell adhesion, we performed a Western blot
analysis of 1 integrins expressed at various time points
following PMA treatment (Fig. 5B). At 4 h, there was no apparent alteration in glycosylation, as evidenced by a lack of change
in 1 integrin electrophoretic mobility. At 7 h
following PMA treatment, the more rapidly migrating 1
isoform (the hyposialylated form) was observed, although clearly some
wild type integrin was still present. Nearly all of the
1 integrin appeared to be hyposialylated at 12 following
PMA treatment (Fig. 5B), and expression of the hyposialylated form was sustained at 15 h (Fig. 1A).
These data suggest that the expression of a hyposialylated integrin
begins between 4 and 7 h following PMA treatment and reaches a
maximum by 12-15 h. Thus, the expression of the hyposialylated
glycoform is temporally correlated with the delayed phase of
PMA-dependent cell adhesion to fibronectin.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 5.
The expression of a hyposialylated
1 integrin isoform is temporally
correlated with the delayed phase of PMA-dependent cell
adhesion to fibronectin. A, U937 cells were treated with 50 ng/ml PMA and then seeded into low attachment tissue culture dishes. At
selected time points following the addition of PMA, cells were removed
from the dishes and reseeded onto standard tissue culture dishes that
had been precoated with 20 µg/ml fibronectin. Cell adhesion to
fibronectin was then quantified as described previously. As shown, PMA
induced both a rapid, but transient (0.5-3 h), and delayed (7-15 h)
increase in cell adhesion to fibronectin. A representative time course
experiment is depicted. Similar results were observed in five
additional experiments performed in either duplicate or triplicate.
B, U397 cells were treated in the presence or absence of 50 ng/ml PMA for selected time points. The cells were then lysed and
Western blotting was performed to detect the 1 integrin.
Note that the more rapidly migrating 1 integrin isoform
(the hyposialylated form) was observed at 7 and 12 h, but not at
4 h, following PMA treatment, suggesting that the expression of
this isoform is temporally correlated with the delayed phase of
PMA-dependent cell adhesion to fibronectin.
|
|
Inhibiting the Expression of Hyposialylated 1
Integrins Blocks the Delayed Phase of PMA-induced Cell Adhesion to
Fibronectin--
To further address the hypothesis that the expression
of a hyposialylated 1 integrin glycoform is associated
with altered integrin function, we treated cells with brefeldin A, a
reagent that disrupts the Golgi apparatus, and then performed cell
adhesion assays. We anticipated that brefeldin A treatment would block the expression of the hyposialylated 1 integrin
glycoform, and thus inhibit the delayed, but not the early, phase of
cell adhesion to fibronectin. Accordingly, we examined
PMA-dependent cell binding to fibronectin at two time
points following brefeldin A treatments. First, we pretreated cells for
2 h with 20 µg/ml brefeldin A. PMA was then added to the
brefeldin A-containing media, and cells were incubated with both PMA
and brefeldin A for an additional hour. As shown in Fig.
6, brefeldin A had no effect on cell
adhesion to fibronectin following a 1-h treatment with PMA. These data suggest that PMA-induced cell adhesion at this time point does not
require the synthesis of a new integrin species. In addition, these
data indicate that the amount of 1 integrin turnover
that occurs within the 3-h brefeldin A treatment does not substantially affect cell adhesion to fibronectin. We next assessed the effect of
brefeldin A on cell adhesion at 8 h following PMA treatment. Brefeldin A was added at 5 h following the initiation of PMA
treatment, a time point when binding is diminished, and then cell
adhesion was examined 3 h later. As shown, brefeldin A
significantly inhibited the enhanced cell adhesion that occurs at
8 h following PMA treatment. These data suggest that the
expression of a new integrin species, presumably the hyposialylated
1 integrin isoform, was required for the delayed phase
of PMA-induced cell adhesiveness.

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 6.
The Golgi-disrupting agent, brefeldin A,
blocks the delayed, but not the early, phase of
PMA-dependent cell adhesion to fibronectin. To
determine whether the expression of a hyposialylated 1
integrin was required for PMA-dependent cell adhesion to
fibronectin, U937 cells were preincubated for 3 h with brefeldin A
to disrupt the Golgi apparatus and were then evaluated for cell
adhesion to fibronectin. As shown, brefeldin A did not block the
binding of cells exposed to PMA for 1 h, suggesting that synthesis
of a new integrin species was not required for the early phase of
PMA-dependent cell adhesion. However, as indicated
(asterisk), fibronectin binding was significantly inhibited
by brefeldin A when binding was assayed at 8 h following PMA
treatment (p < 0.05, as evaluated by a Student's
t test). Data shown represent the mean and S.E. for four
independent experiments performed in duplicate or triplicate.
|
|
Desialylated, Purified 5 1 Integrins
Demonstrate Enhanced Fibronectin Binding--
Previous studies have
shown that the enzymatic removal of sialic acids from the cell surface
can modulate cell adhesion to extracellular matrix ligands (19, 20).
However, because multiple cell surface receptors are likely to be
affected by the desialylating enzyme, it is not currently clear to what
extent desialylation modifies 1 integrin function
directly. To address the hypothesis that unsialylated 1
integrins exhibit better binding to fibronectin, we developed a novel
method to desialylate purified 1 integrins and then
monitor fibronectin binding using a modified ELISA assay (see
"Experimental Procedures"). Briefly, purified
5 1 integrins (that were confirmed to
carry 2-6 sialic acid residues, see Fig. 7C) were treated with or
without sialidase and were then added to fibronectin-coated dishes and
allowed to adhere for 1 h at 37 °C. Bound integrins were
detected by ELISA assay, using the anti- 1 integrin
antibody, MAB2000 (Chemicon International). As shown in Fig.
7A, 5 1 integrins that had been
desialylated demonstrated significantly enhanced attachment to
fibronectin, relative to 5 1 integrins
with 2-6-linked sialic acid sugars. These data imply that
unsialylated 1 integrins are more adhesive to
fibronectin, although desialylation of 5 subunits may
also contribute to increased ligand binding. Importantly, the results
garnered from binding assays with purified integrins suggest that
sialic acid residues play a direct role in the ligand/receptor
interaction.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 7.
Sialidase-treated, purified
5 1
integrins demonstrate enhanced binding to fibronectin.
A, purified 5 1 integrins were
incubated in the presence or absence of agarose-conjugated Vibrio
cholerae neuraminidase (sialidase) for 3 h at 37 °C.
Samples were centrifuged to remove the sialidase, and the
integrin-containing supernatants were loaded onto tissue culture dishes
that had been precoated with varying amounts of fibronectin. Integrin
binding to the dishes was quantitated using a modified ELISA assay (see
"Experimental Procedures"). Where indicated (asterisk),
the amount of fibronectin binding by sialidase-treated integrins was
significantly greater than binding by control integrins
(p < 0.05, evaluated by a Student's t
test). Values represent the mean and S.E. for three experiments
performed in duplicate. B, untreated and sialidase-treated
purified 5 1 integrins were resolved by
SDS-PAGE, then Western-blotted to detect the 1 integrin.
As shown, sialidase-treated integrins demonstrated a more rapid
electrophoretic mobility, consistent with the loss of sialic acids.
C, untreated and sialidase-treated purified
5 1 integrins were precipitated by SNA
lectin, resolved by SDS-PAGE, then Western-blotted for the
1 integrin. A significantly lower level of
1 integrin was observed in SNA precipitates of
sialidase-treated samples, confirming that the sialidase treatment
protocol was highly efficient.
|
|
To verify that 2-6 sialic acid sugars were cleaved from
1 integrins by the sialidase enzyme, 1
integrins were Western blotted to assay for changes in electrophoretic
mobility. As shown in Fig. 7B, sialidase-treated
1 integrins had a more rapid electrophoretic mobility
than untreated 1 integrins, consistent with the loss of
sialic acid residues. In addition, a marked reduction was noted in the
amount of 1 integrins precipitated by the SNA lectin
(Fig. 7C), further confirming that sialidase treatment was
highly efficient in removing 2-6 sialic acid sugars.
 |
DISCUSSION |
In the present study we have investigated the mechanisms that
underlie the PMA-induced adhesion of myeloid cells to fibronectin. In
particular, we have shown that PMA treatment has a multiphasic effect
on cell adhesiveness. PMA induces a rapid increase in adhesion, followed by a diminution at 3-5 h, and then a second phase of enhanced
adhesion that begins by about 7 h, and is sustained for at least
15 h. Our results suggest that this second phase of enhanced cell
adhesion is due to the PMA-dependent expression of a
1 integrin glycoform that is lacking in the negatively
charged sugar, 2-6 sialic acid. The expression of this
hyposialylated 1 integrin glycoform is highly correlated
temporally with the delayed phase of cell adhesion. Expression of the
hyposialylated form begins at some time between 4 and 7 h
following PMA treatment, is expressed with increasingly greater
abundance until ~12 h, and is sustained for at least 15 h.
Importantly, the delayed phase of PMA-dependent cell
adhesion is inhibited when the Golgi disrupter, brefeldin A, is used to
block the expression of the hyposialylated form.
In contrast to the delayed phase, the rapid phase of
PMA-dependent fibronectin binding does not appear to be
dependent upon the expression of a variant integrin glycoform, because
brefeldin A had no significant effect when adhesion is assayed at early time points following PMA treatment (Fig. 6). Moreover, the
hyposialylated integrin glycoform is not expressed within the first
4 h following PMA treatment (Fig. 5B). It is likely
that the rapid increase in cell adhesiveness is due to the
PMA-dependent activation of pre-existing integrin
receptors. It has been well-established, particularly in hematopoietic
cells, that integrins are activated by "inside-out" signaling
events (21, 22). Alternately, it has been suggested that PMA may
stimulate cell adhesion by modulating events that lie downstream of the
integrin-ligand interaction (23, 24). Clearly, further experiments will
be required to elucidate the mechanisms that underlie the early phase
of PMA-dependent myeloid cell adhesion.
Our results suggest that the PMA-dependent expression of a
hyposialylated 1 integrin glycoform is due, at least in
part, to the down-regulation of the ST6Gal I sialyltransferase.
Expression of the ST6Gal I sialyltransferase is known to be
developmentally regulated (25, 26), and the levels of this enzyme vary
in response to cell differentiation status (27-29). In our study, two
myeloid cell lines that normally undergo differentiation in response to
PMA (U937 and THP-1 cells) were shown to have decreased levels of
ST6Gal I following PMA treatment. Consistent with these results, PMA
has been previously shown to down-regulate ST6Gal I in HL-60 myeloid
cells (27). Unlike U937 and THP-1 cells, myeloid cells that have been
selected for PMA resistance (PRU cells) do not down-regulate ST6Gal I
in response to PMA, do not express hyposialylated 1
integrins, and, finally, do not bind to fibronectin following PMA
treatment. Collectively, these results suggest that the
1 integrin is an important substrate for ST6Gal I and
that integrin function may be regulated by the level of 2-6 sialylation.
Several studies support a role for integrin carbohydrate groups in
regulating the association between integrins and ligand. Akiyama
et al. (30) reported that the treatment of human foreskin fibroblasts with glycosylation inhibitors blocked cell adhesion to
fibronectin. Similarly, Zheng et al. (20) demonstrated that ligand binding was altered when N-linked
carbohydrates were enzymatically cleaved from cell surface
5 1 integrins. In our study, purified 5 1 integrins were treated with sialidase
enzyme to recapitulate the hyposialylated integrins expressed by
PMA-treated myeloid cells. Importantly, enzymatically desialylated
5 1 integrins demonstrated enhanced
binding to fibronectin, consistent with the observation that myeloid
cells expressing hyposialylated 1 integrins adhere
better to fibronectin. The enhanced binding of desialylated, purified
integrins supports the hypothesis that the presence of sialic acids can
directly modulate the ligand/receptor interaction.
Accumulating evidence suggests that, in hematopoietic
cells, sialylation of cell surface receptors is inversely correlated with cell adhesion to extracellular matrix ligands (13, 19, 31),
although this has not been universally observed (14). In one study, the
enzymatic removal of sialic acid residues from the surface of HL60
cells stimulated cell adhesion to fibronectin (19). This enhanced
binding was thought to be due to altered activity of the
1 integrin, because 1 integrins from
sialidase-treated cells expressed elevated levels of a
1-specific activation epitope. The mechanism by which
sialylation of 1 integrins alters integrin function is
currently unclear. It has been suggested that sialic acid residues can
mask important functional domains on membrane receptors (32).
Alternately, sialic acids, due to their negative charge, could affect
protein conformation.
Clearly, 1 integrin function can be modulated by
pharmacologic or enzymatic reagents that alter the composition of
integrin carbohydrates. However, there is also substantial evidence
that, in vivo, 1 integrins undergo changes in
carbohydrate composition in response to physiologic stimuli. Variant
1 integrin glycoforms have been observed in multiple
cell types, and the expression of a variant glycoform is typically
associated with a profound change in cell phenotype (11-14, 18,
33-40). For example, changes in 1 integrin sialylation
have been observed in differentiating thymocytes (13). Modifications in
1 integrin glycosylation are also correlated with
alterations in cell migratory or invasive capability. The highly
invasive cytotrophoblasts harvested from early stage human placentas
have hyposialylated 1 integrins, as compared with
1 integrins expressed by the less invasive
cytotrophoblasts of later stage placentas (12). Similarly, the
1 integrins of activated keratinocytes, which
demonstrate enhanced migration on fibronectin, have a different
glycosylation pattern than naive keratinocytes (34). Finally, variant
1 glycoforms have been observed in numerous transformed
and metastatic cells (11, 35-40). The finding that variant
1 integrins are expressed by multiple and diverse cell
types, under conditions that promote long term changes in cell
adhesiveness and motility, strongly suggests that variant
1 glycoforms are functionally important.
Although our results implicate differentially 2-6-sialylated
1 integrin subunits in regulating fibronectin receptor
function, the potential role of differentially glycosylated
integrin subunits has not yet been clarified. It was previously
reported that the 5 integrin subunits expressed by G361
melanoma cells are modified by 2-8-linked oligosialic acids (41).
The enzymatic removal of these polysialic acid moieties inhibited G361
cell adhesion to fibronectin, implicating 5
carbohydrates in ligand binding (41). N-Linked glycosylation
of 5 may also indirectly modulate fibronectin binding by
mediating the association of 5 with other membrane
components. Wang et al. (42) reported that epithelial cell
adhesion to fibronectin was inhibited by the binding of GT1b gangliosides to the carbohydrate domain of integrin 5.
Finally, N-linked carbohydrates may regulate the
localization of 5 subunits to a glycolipid-rich plasma
membrane microdomain (43). Collectively, these data suggest that
glycosylation of 5 integrin subunits may be important
for fibronectin binding; however, it remains to be determined whether
5 integrins undergo differential glycosylation in
response to signal transduction cascades, as we have observed for
1 integrins.
In light of evidence implicating glycosylation, and particularly
sialylation, as a modulator of cell adhesion, we propose that inducible
changes in carbohydrate composition represent an important and novel
mechanism for regulation of the 1 integrin receptor. Our
studies suggest that activation of a PMA-stimulated signaling cascade
causes the down-regulation of the ST6Gal I sialyltransferase, which, in
turn, leads to the expression of hyposialylated 1
integrins that bind fibronectin more actively. The expression of
hyposialylated 1 integrin glycoforms likely plays a key
role in mediating the prolonged fibronectin-binding capability of
differentiated myeloid cells.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grants RO1 CA84248 (to S. L. B.), 5 P60 AR 20614-23 (to S. L. B.), Hl5400 (to E. A. E.), and RO1 GM48134 (to K. J. C.), by a Veterans Administration Merit Review (to E. A. E.), and by a grant from the
University of Alabama Cell Adhesion and Matrix Research Center (to
S. L. B.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of
Physiology and Biophysics, Rm. 982A McCallum Building, 1918 University Blvd., Birmingham, AL 35294. Tel.: 205-934-3441; Fax:
205-975-9028; E-mail: bellis@ physiology.uab.edu.
Published, JBC Papers in Press, June 28, 2002, DOI 10.1074/jbc.M202493200
 |
ABBREVIATIONS |
The abbreviations used are:
PMA, phorbol
myristate acetate;
HRP, horseradish peroxidase;
MAA, Maackia
amurensis;
PBS, phosphate-buffered saline;
SNA, Sambucus
nigra;
PNGase F, N-glycosidase F;
ELISA, enzyme-linked immunosorbent assay;
BSA, bovine serum albumin.
 |
REFERENCES |
| 1.
|
Tenen, D. G.,
Hromas, R.,
Licht, J. D.,
and Zhang, D. E.
(1997)
Blood
90,
489-519[Free Full Text]
|
| 2.
|
Boles, B. K.,
Ritzenthaler, J.,
Birkenmeier, T.,
and Roman, J.
(2000)
Am. J. Physiol.
278,
L703-L712[Abstract/Free Full Text]
|
| 3.
|
Shimizu, Y.,
Rose, D. M.,
and Ginsberg, M. H.
(1999)
Adv. Immunol.
72,
325-380[Medline]
[Order article via Infotrieve]
|
| 4.
|
Aplin, A. E.,
Howe, A.,
Alahari, S. K.,
and Juliano, R. L.
(1998)
Pharmacol. Rev.
50,
197-263[Abstract/Free Full Text]
|
| 5.
|
Bellon, T.,
Lopez-Rodriguez, C.,
Rubio, M. A.,
Jochems, G.,
Bernabeu, C.,
and Corbi, A. L.
(1994)
Eur. J. Immunol.
24,
41-47[Medline]
[Order article via Infotrieve]
|
| 6.
|
Ferreira, O. C., Jr.,
Valinsky, J. E.,
Sheridan, K.,
Wayner, E. A.,
Bianco, C.,
and Garcia-Pardo, A.
(1991)
Exp. Cell Res.
193,
20-26[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Laouar, A.,
Collart, F. R.,
Chubb, C. B.,
Xie, B.,
and Huberman, E.
(1999)
J. Immunol.
162,
407-414[Abstract/Free Full Text]
|
| 8.
|
Van de Water, L.,
Aronson, D.,
and Braman, V.
(1988)
Cancer Res.
48,
5730-5737[Abstract/Free Full Text]
|
| 9.
|
Heino, J.,
Ignotz, R. A.,
Hemler, M. E.,
Crouse, C.,
and Massague, J.
(1989)
J. Biol. Chem.
264,
380-388[Abstract/Free Full Text]
|
| 10.
|
Lenter, M.,
and Vestweber, D.
(1994)
J. Biol. Chem.
269,
12263-12268[Abstract/Free Full Text]
|
| 11.
|
Asada, M.,
Furukawa, K.,
Segawa, K.,
Endo, T.,
and Kobata, A.
(1997)
Cancer Res.
57,
1073-1080[Abstract/Free Full Text]
|
| 12.
|
Moss, L.,
Prakobphol, A.,
Wiedmann, T. W.,
Fisher, S. J.,
and Damsky, C. H.
(1994)
Glycobiology
4,
567-575[Abstract/Free Full Text]
|
| 13.
|
Wadsworth, S.,
Halvorson, M. J.,
Chang, A. C.,
and Coligan, J. E.
(1993)
J. Immunol.
150,
847-857[Abstract]
|
| 14.
|
Symington, B. E.,
Symington, F. W.,
and Rohrschneider, L. R.
(1989)
J. Biol. Chem.
264,
13258-13266[Abstract/Free Full Text]
|
| 15.
|
Heino, J.,
and Massague, J.
(1989)
J. Biol. Chem.
264,
21806-21811[Abstract/Free Full Text]
|
| 16.
|
Akiyama, S. K.,
and Yamada, K. M.
(1987)
J. Biol. Chem.
262,
17536-17542[Abstract/Free Full Text]
|
| 17.
|
Ignotz, R. A.,
and Massague, J.
(1987)
Cell
51,
189-197[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Bellis, S. L.,
Newman, E.,
and Friedman, E. A.
(1999)
J. Cell. Physiol.
181,
33-44[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Pretzlaff, R. K.,
Xue, V. W.,
and Rowin, M. E.
(2000)
Cell Adhes. Commun.
7,
491-500[Medline]
[Order article via Infotrieve]
|
| 20.
|
Zheng, M.,
Fang, H.,
and Hakomori, S.
(1994)
J. Biol. Chem.
269,
12325-12331[Abstract/Free Full Text]
|
| 21.
|
Diamond, M. S.,
and Springer, T. A.
(1994)
Curr. Biol.
4,
506-517[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Stewart, M.,
Thiel, M.,
and Hogg, N.
(1995)
Curr. Opin. Cell Biol.
7,
690-696[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Danilov, Y. N.,
and Juliano, R. L.
(1989)
J. Cell Biol.
108,
1925-1933[Abstract/Free Full Text]
|
| 24.
|
Faull, R. J.,
Kovach, N. L.,
Harlan, J. M.,
and Ginsberg, M. H.
(1994)
J. Exp. Med.
179,
1307-1316[Abstract/Free Full Text]
|
| 25.
|
Dall'Olio, F.,
Malagolini, N., Di,
Stefano, G.,
Ciambella, M.,
and Serafini-Cessi, F.
(1990)
Biochem. J.
270,
519-524[Medline]
[Order article via Infotrieve]
|
| 26.
|
Vertino-Bell, A.,
Ren, J.,
Black, J. D.,
and Lau, J. T.
(1994)
Dev. Biol.
165,
126-136[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Taniguchi, A.,
Higai, K.,
Hasegawa, Y.,
Utsumi, K.,
and Matsumoto, K.
(1998)
FEBS Lett.
441,
191-194[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Dall'Olio, F.,
Malagolini, N.,
Guerrini, S.,
Lau, J. T.,
and Serafini-Cessi, F.
(1996)
Glycoconj. J.
13,
115-121[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Dall'Olio, F.,
Malagolini, N.,
and Serafini-Cessi, F.
(1992)
Biochem. Biophys. Res. Commun.
184,
1405-1410[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Akiyama, S. K.,
Yamada, S. S.,
and Yamada, K. M.
(1989)
J. Biol. Chem.
264,
18011-18018[Abstract/Free Full Text]
|
| 31.
|
Le Marer, N.,
and Skacel, P. O.
(1999)
J. Cell. Physiol.
179,
315-324[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Razi, N.,
and Varki, A.
(1999)
Glycobiology
9,
1225-1234[Abstract/Free Full Text]
|
| 33.
|
Braut-Boucher, F.,
Font, J.,
Pichon, J.,
Paulin, Y.,
Boukhelifa, M.,
Aubery, M.,
and Derappe, C.
(1998)
Leuk. Res.
22,
947-952[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Kim, L. T.,
Ishihara, S.,
Lee, C. C.,
Akiyama, S. K.,
Yamada, K. M.,
and Grinnell, F.
(1992)
J. Cell Sci.
103,
743-753[Abstract]
|
| 35.
|
von Lampe, B.,
Stallmach, A.,
and Riecken, E. O.
(1993)
Gut
34,
829-836[Abstract/Free Full Text]
|
| 36.
|
Veiga, S. S.,
Chammas, R.,
Cella, N.,
and Brentani, R. R.
(1995)
Int. J. Cancer
61,
420-424[Medline]
[Order article via Infotrieve]
|
| 37.
|
Oz, O. K.,
Campbell, A.,
and Tao, T. W.
(1989)
Int. J. Cancer
44,
343-347[Medline]
[Order article via Infotrieve]
|
| 38.
|
Leppa, S.,
Heino, J.,
and Jalkanen, M.
(1995)
Cell Growth Differ.
6,
853-861[Abstract]
|
| 39.
|
Jasiulionis, M. G.,
Chammas, R.,
Ventura, A. M.,
Travassos, L. R.,
and Brentani, R. R.
(1996)
Cancer Res.
56,
1682-1689[Abstract/Free Full Text]
|
| 40.
|
Yan, Z.,
Chen, M.,
Perucho, M.,
and Friedman, E.
(1997)
J. Biol. Chem.
272,
30928-30936[Abstract/Free Full Text]
|
| 41.
|
Nadanaka, S.,
Sato, C.,
Kitajima, K.,
Katagiri, K.,
Irie, S.,
and Yamagata, T.
(2001)
J. Biol. Chem.
276,
33657-33664[Abstract/Free Full Text]
|
| 42.
|
Wang, X.,
Sun, P., Al-,
Qamari, A.,
Tai, T.,
Kawashima, I.,
and Paller, A. S.
(2001)
J. Biol. Chem.
276,
8436-8444[Abstract/Free Full Text]
|
| 43.
|
Kazui, A.,
Ono, M.,
Handa, K.,
and Hakomori, S.
(2000)
Biochem. Biophys. Res. Commun.
273,
159-163[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. Kitazume, R. Oka, K. Ogawa, S. Futakawa, Y. Hagiwara, H. Takikawa, M. Kato, A. Kasahara, E. Miyoshi, N. Taniguchi, et al.
Molecular insights into {beta}-galactoside {alpha}2,6-sialyltransferase secretion in vivo
Glycobiology,
May 1, 2009;
19(5):
479 - 487.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Isaji, Y. Sato, T. Fukuda, and J. Gu
N-Glycosylation of the I-like Domain of {beta}1 Integrin Is Essential for {beta}1 Integrin Expression and Biological Function: IDENTIFICATION OF THE MINIMAL N-GLYCOSYLATION REQUIREMENT FOR {alpha}5{beta}1
J. Biol. Chem.,
May 1, 2009;
284(18):
12207 - 12216.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Sato, T. Isaji, M. Tajiri, S. Yoshida-Yamamoto, T. Yoshinaka, T. Somehara, T. Fukuda, Y. Wada, and J. Gu
An N-Glycosylation Site on the{beta}-Propeller Domain of the Integrin {alpha}5 Subunit Plays Key Roles in Both Its Function and Site-specific Modification by{beta}1,4-N-Acetylglucosaminyltransferase III
J. Biol. Chem.,
May 1, 2009;
284(18):
11873 - 11881.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Diskin, Z. Cao, H. Leffler, and N. Panjwani
The role of integrin glycosylation in galectin-8-mediated trabecular meshwork cell adhesion and spreading
Glycobiology,
January 1, 2009;
19(1):
29 - 37.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. V. Woodard-Grice, A. C. McBrayer, J. K. Wakefield, Y. Zhuo, and S. L. Bellis
Proteolytic Shedding of ST6Gal-I by BACE1 Regulates the Glycosylation and Function of {alpha}4{beta}1 Integrins
J. Biol. Chem.,
September 26, 2008;
283(39):
26364 - 26373.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Zhuo, R. Chammas, and S. L. Bellis
Sialylation of {beta}1 Integrins Blocks Cell Adhesion to Galectin-3 and Protects Cells against Galectin-3-induced Apoptosis
J. Biol. Chem.,
August 8, 2008;
283(32):
22177 - 22185.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Lee, H.-J. Lee, S. Bae, and Y.-S. Lee
Protein Sialylation by Sialyltransferase Involves Radiation Resistance
Mol. Cancer Res.,
August 1, 2008;
6(8):
1316 - 1325.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Bei, Y. Lu, S. L. Bellis, W. Zhou, E. Horvath, and E. A. Eklund
Identification of a HoxA10 Activation Domain Necessary for Transcription of the Gene Encoding beta3 Integrin during Myeloid Differentiation
J. Biol. Chem.,
June 8, 2007;
282(23):
16846 - 16859.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Isaji, Y. Sato, Y. Zhao, E. Miyoshi, Y. Wada, N. Taniguchi, and J. Gu
N-Glycosylation of the beta-Propeller Domain of the Integrin {alpha}5 Subunit Is Essential for {alpha}5beta1 Heterodimerization, Expression on the Cell Surface, and Its Biological Function
J. Biol. Chem.,
November 3, 2006;
281(44):
33258 - 33267.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Chiricolo, N. Malagolini, S. Bonfiglioli, and F. Dall'Olio
Phenotypic changes induced by expression of {beta}-galactoside {alpha}2,6 sialyltransferase I in the human colon cancer cell line SW948
Glycobiology,
February 1, 2006;
16(2):
146 - 154.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. C. Seales, F. M. Shaikh, A. V. Woodard-Grice, P. Aggarwal, A. C. McBrayer, K. M. Hennessy, and S. L. Bellis
A Protein Kinase C/Ras/ERK Signaling Pathway Activates Myeloid Fibronectin Receptors by Altering {beta}1 Integrin Sialylation
J. Biol. Chem.,
November 11, 2005;
280(45):
37610 - 37615.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. C. Seales, G. A. Jurado, B. A. Brunson, J. K. Wakefield, A. R. Frost, and S. L. Bellis
Hypersialylation of {beta}1 Integrins, Observed in Colon Adenocarcinoma, May Contribute to Cancer Progression by Up-regulating Cell Motility
Cancer Res.,
June 1, 2005;
65(11):
4645 - 4652.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Hu, R. Xu, G. Zhang, J. Jin, Z. M. Szulc, J. Bielawski, Y. A. Hannun, L. M. Obeid, and C. Mao
Golgi Fragmentation Is Associated with Ceramide-induced Cellular Effects
Mol. Biol. Cell,
March 1, 2005;
16(3):
1555 - 1567.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. H. Marino, M. Hoffman, M. Meyer, and K. S. Miller
Sialyltransferase mRNA abundances in B cells are strictly controlled, correlated with cognate lectin binding, and differentially responsive to immune signaling in vitro
Glycobiology,
December 1, 2004;
14(12):
1265 - 1274.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Clement, J. Rocher, G. Loirand, and J. Le Pendu
Expression of sialyl-Tn epitopes on {beta}1 integrin alters epithelial cell phenotype, proliferation and haptotaxis
J. Cell Sci.,
October 1, 2004;
117(21):
5059 - 5069.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Moro, E. Perlino, E. Marra, L. R. Languino, and M. Greco
Regulation of {beta}1C and {beta}1A Integrin Expression in Prostate Carcinoma Cells
J. Biol. Chem.,
January 16, 2004;
279(3):
1692 - 1702.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Caruso, M. Cavaldesi, M. Gentile, O. Sthandier, P. Amati, and M.-I. Garcia
Role of sialic acid-containing molecules and the {alpha}4{beta}1 integrin receptor in the early steps of polyomavirus infection
J. Gen. Virol.,
November 1, 2003;
84(11):
2927 - 2936.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|